CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) saw a significant increase in short interest in September. As of September 15th, there was short interest totaling 239,903 shares, an increase of 467.9% from the August 31st total of 42,243 shares. Approximately 32.9% of the company’s shares are short sold. Based on an average trading volume of 6,870,827 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

A number of brokerages have issued reports on CDT. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research report on Monday. Wall Street Zen upgraded CDT Equity from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

CDT Equity Stock Performance

Shares of CDT stock opened at $0.12 on Friday. The stock has a 50 day moving average price of $1.99 and a 200 day moving average price of $24.43. CDT Equity has a 52-week low of $0.12 and a 52-week high of $1,778.00. The firm has a market capitalization of $95,590.00, a P/E ratio of -0.00 and a beta of 1.48.

CDT Equity (NASDAQ:CDT) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

About CDT Equity

CDT Equity, Inc, traded on the Nasdaq under the symbol CDT, is associated with Conduit Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune and inflammatory diseases.

The company’s business model centers on acquiring and advancing clinical-stage drug candidates through partnerships with academic institutions and pharmaceutical companies. Its portfolio has included investigational therapies intended to address conditions such as systemic sclerosis and other immune-mediated diseases, although the status and composition of its development programs may change as clinical and corporate activities progress.

Conduit Pharmaceuticals was established to help translate externally developed drug candidates into commercial medicines.